PREVNAR-13 is being discontinued by the manufacturer April 30, 2024
Pediatrics: PREVNAR-13 is approved for children age 2 months to 59 months or high risk children 60 months to 71 months, where outpatient administration of the vaccine is not desirable.
Adults: PREVNAR-13 is also approved for use in adults, 19 years and older who have immunocompromised conditions, functional or anatomic asplenia, CSF leaks, or cochlear implants.
Add Formweb to your mobile device
PREVNAR-13 is being discontinued by the manufacturer April 30, 2024
Pediatrics: PREVNAR-13 is approved for children age 2 months to 59 months or high risk children 60 months to 71 months, where outpatient administration of the vaccine is not desirable.
Adults: PREVNAR-13 is also approved for use in adults, 19 years and older who have immunocompromised conditions, functional or anatomic asplenia, CSF leaks, or cochlear implants.
Reviewed: November 13, 2012